Announcements
- Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
- Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
- Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Tuesday, Crinetics Pharmaceuticals Inc (6Z4:MUN) closed at 40.60, -9.38% below its 52-week high of 44.80, set on Apr 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 40.60 |
---|---|
High | 40.60 |
Low | 40.60 |
Bid | 41.20 |
Offer | 41.40 |
Previous close | 40.40 |
Average volume | 53.90 |
---|---|
Shares outstanding | 77.93m |
Free float | 74.94m |
P/E (TTM) | -- |
Market cap | 3.39bn USD |
EPS (TTM) | -3.70 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 07:04 BST.
More ▼